Phase 2
N=10
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
Head and Neck Cancer
Bottom Line
View on ClinicalTrials.gov: NCT04313504 ↗Enrolled (actual)
10
Serious AEs
60.0%
Results posted
May 2026
Primary outcome: Primary: Overall Response — 0; 1; 1; 8 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Niraparib (Drug); Dostarlimab (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Trisha Wise-Draper
- Primary completion
- Jun 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Response |
0; 1; 1; 8 | — |
| SECONDARY Progression Free Survival |
3.8 | — |
| SECONDARY Overall Survival |
10.1 | — |
Summary
The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.
Eligibility Criteria
Inclusion Criteria
- Histologically, cytologically, or radiographically confirmed recurrent or metastatic non cutaneous HNSCC for which there are no surgical or radiation curative options.
- ECOG performance status ≤2
- Patients must be able to swallow pills
Exclusion Criteria
- Nasopharyngeal and salivary gland tumors
- Patients who have not recovered from adverse events due to prior anti-cancer therapy with the exception of alopecia
- Prior exposure to both immunotherapy drugs (PD-1, PDL-1, CTLA-4 inhibitors) and PARP inhibitors. Single exposure to either immunotherapy or PARP inhibitors is allowable.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to niraparib or dostarlimab.
- Patients with uncontrolled intercurrent illness.
- Requirement of any use of steroids greater than the equivalent of 10mg prednisone daily is not allowed.
Data sourced from ClinicalTrials.gov (NCT04313504). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.